Clinical Trials Logo

Oxaliplatin clinical trials

View clinical trials related to Oxaliplatin.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05841134 Not yet recruiting - Capecitabine Clinical Trials

Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal Cancer

Start date: June 1, 2023
Phase: Phase 2
Study type: Interventional

This study is a multi-center, single-arm, open-label phase II clinical trial, aiming to observe and evaluate the perioperative treatment of tislelizumab combined with chemotherapy (CAPOX) in stage II or III colorectal cancer with MSI-H/dMMR Patient efficacy and safety.

NCT ID: NCT05798884 Not yet recruiting - Colorectal Cancer Clinical Trials

Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients

Start date: May 2023
Phase: N/A
Study type: Interventional

In this study, a 24-week randomized, sham-controlled, single-blind, multicenter clinical trial will be conducted to explore the effect of electroacupuncture for prevention and treatment of both acute and chronic neurotoxicity through both clinical and biological indicators.

NCT ID: NCT05218148 Not yet recruiting - Immunotherapy Clinical Trials

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

The SOX regimen has became the standard perioperative chemotherapy for locally advanced gastric cancer; The immune checkpoint inhibitors have become a standard treatment for advanced or metastatic gastric cancer;For HER2-positive locally advanced gastric cancer, some phase II studies have shown that chemotherapy combined with trastuzumab can further improve the pathological remission rate;This prospective phase II clinical trial was designed, using SOX combined with sintilimab and trastuzumab to treat HER2 positive locally advanced gastric or gastroesophageal junction adenocarcinoma patients.

NCT ID: NCT04962958 Not yet recruiting - Clinical trials for Carcinoma, Hepatocellular

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label,multi-center ,non-randomized ,single arm exploratory study . This clinical study is an investigator-initiated clinical trial(IIT ). The objective of this study is to evaluate if the addition of hepatic artery infusion chemotherapy (HAIC) and Donafenib after curative resection for hepatocellular carcinoma patients with a solitary tumor≥5 cm and microvascular invasion (MVI) will prevent or delay the recurrence of the disease.

NCT ID: NCT04627363 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm clinical study to preliminarily observe and evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin synchronous combined with Bevacizumab and Toripalimab as the first-line therapy for advanced HCC.